BRIEF-Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For Investigational Oral GLP-1 Receptor Agonist

Reuters2024-12-18

Dec 18 (Reuters) - Merck & Co Inc MRK.N:

MERCK ENTERS INTO EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH HANSOH PHARMA FOR INVESTIGATIONAL ORAL GLP-1 RECEPTOR AGONIST
MERCK & CO INC - HANSOH PHARMA TO RECEIVE $112 MILLION UPFRONT, UP TO $1.9 BILLION IN MILESTONES
MERCK & CO INC - MERCK WILL RECORD A PRE-TAX CHARGE OF $112 MILLION, OR $0.04 PER SHARE, TO BE INCLUDED IN GAAP AND NON-GAAP RESULTS IN Q4 OF 2024
MERCK & CO INC - TO RECORD $112 MILLION PRE-TAX CHARGE IN Q4 2024

Source text: ID:nBw8jztsha

Further company coverage: MRK.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492904299?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-18 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492904299","market":"us","top_or_hot":-1,"title":"BRIEF-Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For Investigational Oral GLP-1 Receptor Agonist","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For Investigational Oral GLP-1 Receptor Agonist</title></head><body><p><span>Dec 18 (Reuters)</span><span> - </span>Merck &amp; Co Inc <span>MRK.N</span>:</p><ul><li><p>MERCK ENTERS INTO EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH HANSOH PHARMA FOR INVESTIGATIONAL ORAL GLP-1 RECEPTOR AGONIST</p></li><li><p>MERCK &amp; CO INC - HANSOH PHARMA TO RECEIVE $112 MILLION UPFRONT, UP TO $1.9 BILLION IN MILESTONES</p></li><li><p>MERCK &amp; CO INC - MERCK WILL RECORD A PRE-TAX CHARGE OF $112 MILLION, OR $0.04 PER SHARE, TO BE INCLUDED IN GAAP AND NON-GAAP RESULTS IN Q4 OF 2024</p></li><li><p>MERCK &amp; CO INC - TO RECORD $112 MILLION PRE-TAX CHARGE IN Q4 2024</p></li></ul><p>Source text: <span>ID:nBw8jztsha</span></p><p>Further company coverage: <span>MRK.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For Investigational Oral GLP-1 Receptor Agonist</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For Investigational Oral GLP-1 Receptor Agonist\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 19:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUABPDZLX:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For Investigational Oral GLP-1 Receptor AgonistDec 18 (Reuters) - Merck & Co Inc MRK.N:MERCK ENTERS INTO EXCLUSIVE GLOBAL ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUABPDZLX:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014575.USD","symbol_name":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUABPDZLX:1","article_id":"2492904299","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492904299","pubTimestamp":1734522399,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For Investigational Oral GLP-1 Receptor AgonistDec 18 (Reuters) - Merck & Co Inc MRK.N:MERCK ENTERS INTO EXCLUSIVE GLOBAL ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4559":"巴菲特持仓","03692":"翰森制药","BK4588":"碎股","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","MRK":"默沙东","BK4516":"特朗普概念","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BK1589":"北水核心资产","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","BK4007":"制药","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC"},"translate_title":"简介-默克与翰森制药就研究性口服GLP-1受体激动剂签订全球独家许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9,"MRK":0.9},"content_text":"BRIEF-Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For Investigational Oral GLP-1 Receptor AgonistDec 18 (Reuters) - Merck & Co Inc MRK.N:MERCK ENTERS INTO EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH HANSOH PHARMA FOR INVESTIGATIONAL ORAL GLP-1 RECEPTOR AGONISTMERCK & CO INC - HANSOH PHARMA TO RECEIVE $112 MILLION UPFRONT, UP TO $1.9 BILLION IN MILESTONESMERCK & CO INC - MERCK WILL RECORD A PRE-TAX CHARGE OF $112 MILLION, OR $0.04 PER SHARE, TO BE INCLUDED IN GAAP AND NON-GAAP RESULTS IN Q4 OF 2024MERCK & CO INC - TO RECORD $112 MILLION PRE-TAX CHARGE IN Q4 2024Source text: ID:nBw8jztshaFurther company coverage: MRK.N ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492904299"}